Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Lymphoplasmacytic Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Nodal Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Recurrent Splenic Marginal Zone Lymphoma Recurrent Waldenstrom Macroglobulinemia Refractory B-Cell Non-Hodgkin Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Refractory Follicular Lymphoma Refractory Lymphoplasmacytic Lymphoma Refractory Nodal Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma Refractory Splenic Marginal Zone Lymphoma Refractory Waldenstrom Macroglobulinemia Richter Syndrome Waldenstrom Macroglobulinemia CLL/SLL (ARM A) ONLY Diagnosis of CLL according to the National Cancer Institute (NCI) or SLL according to the World Health Organization (WHO) criteria; this includes previous documentation of Biopsy-proven small lymphocytic lymphoma or Diagnosis of CLL according to NCI working group as evidenced by all of the following Peripheral blood B cell count of > 5 x 10^9/L consisting of small to moderate size lymphocytes Immunophenotyping consistent with CLL defined as The predominant population of lymphocytes share both B-cell antigens (cluster of differentiation [CD]19, CD20 [typically dim expression] or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.) Clonality as evidenced by kappa or lambda light chain expression (typically dim immunoglobulin expression) or other genetic method (e.g. immunoglobulin heavy chain variable [IGHV] analysis) NOTE: splenomegaly, hepatomegaly, or lymphadenopathy are not required for the diagnosis of CLL Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative fluorescent in situ hybridization (FISH) analysis for t(11;14) (immunoglobulin H [IgH]/cyclin D1 [CCND1]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy  Currently participating in or has participated in a study of an investigational agent or using an investigational device =< 28 days prior to registration Receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy =< 7 days prior to registration Low doses of steroids (=< 20 mg of prednisone or equivalent dose of other steroid/day) Previous use of corticosteroids is allowed After initiation of MK-3475 therapy, steroid can be used for management of potential immune mediated adverse events (AE) for less than 8 weeks of therapy Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are permitted Prior anti-cancer monoclonal antibody =< 28 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier Prior chemotherapy or radiation therapy =< 14 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy